With the booming of ADC development and various challenges confronted in selecting a suitable antibody, toxic payload, and small molecule linker, Creative Biolabs has established a comprehensive ADC development service, committed to offering support for global clients with various aspects of ADC development projects. This brochure presented a case study in which the ADC was developed via trastuzumab and monomethyl auristatin E (MMAE), with Mc-VC-PAB-MMAE (Cat # ADC-S-012) as a payload-linker. Additionally, the formulation of ADC and in vitro efficacy are evaluated and compared to unconjugated trastuzumab. More details about this case study are presented in this brochure.

The following list includes the main content:

1. Introduction
2. Materials and Methods
3. Results